z-logo
Premium
Comparison of two high doses of oral methylprednisolone for multiple sclerosis relapses: a pilot, multicentre, randomized, double‐blind, non‐inferiority trial
Author(s) -
HervásGarcía J. V.,
RamióTorrentà L.,
BrievaRuiz L.,
BatlléNadal J.,
Moral E.,
Blanco Y.,
CanoOrgaz A.,
PresasRodríguez S.,
Torres F.,
Capellades J.,
RamoTello C.
Publication year - 2019
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/ene.13851
Subject(s) - medicine , double blind , multiple sclerosis , pilot trial , methylprednisolone , randomized controlled trial , physical therapy , placebo , alternative medicine , psychiatry , pathology
Background and purpose Oral or intravenous methylprednisolone (≥500 mg/day for 5 days) is recommended for multiple sclerosis (MS) relapses. Nonetheless, the optimal dose remains uncertain. We compared clinical and radiological effectiveness, safety and quality of life (QoL) of oral methylprednisolone [1250 mg/day (standard high dose)] versus 625 mg/day (lesser high dose), both for 3 days] in MS relapses. Methods A total of 49 patients with moderate to severe MS relapse within the previous 15 days were randomized in a pilot, double‐blind, multicentre, non‐inferiority trial (ClinicalTrial.gov, NCT01986998). The primary endpoint was non‐inferiority of the lesser high dose by Expanded Disability Status Scale (EDSS) score improvement on day 30 (non‐inferiority margin, 1 point). The secondary endpoints were EDSS score change on days 7 and 90, changes in T1 gadolinium‐enhanced and new/enlarged T2 lesions on days 7 and 30, and safety and QoL results. Results The primary outcome was achieved [mean (95% confidence interval) EDSS score difference, −0.26 (−0.7 to 0.18) at 30 days ( P  =   0.246)]. The standard high dose yielded a superior EDSS score improvement on day 7 ( P  =   0.028). No differences were observed in EDSS score on day 90 ( P  =   0.352) or in the number of T1 gadolinium‐enhanced or new/enlarged T2 lesions on day 7 ( P  =   0.401, 0.347) or day 30 ( P  =   0.349, 0.529). Safety and QoL were good at both doses. Conclusions A lesser high‐dose oral methylprednisolone regimen may not be inferior to the standard high dose in terms of clinical and radiological response.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here